300
Participants
Start Date
August 15, 2023
Primary Completion Date
January 16, 2025
Study Completion Date
February 22, 2025
Cagrilintide
Participants will receive 2.4 mg cagrilintide subcutaneously.
Semaglutide
Participants will receive 2.4 mg semaglutide subcutaneously.
Placebo Semaglutide
Participants will receive placebo matched to semaglutide subcutaneously.
Placebo Cagrilintide
Participants will receive placebo matched to cagrilintide subcutaneously.
Chinese People's Liberation Army General Hospital-Endocrinology, Beijing
The first hospital of Jilin University, Changchun
The First Bethune hospital of Jilin University-Endocrinology, Changchun
Huashan Hospital Fudan University, Shanghai
Huashan Hospital Fudan University, Jingan/Shanghai
Tongren Hospital Shanghai Jiao Tong Univ. School of Medicine, Shanghai
Central Hospital of Minhang District-Endocrinology, Shanghai
Shanghai Pudong New Area People's Hospital-Endocrinology, Shanghai
The Second Affiliated Hospital of Nanjing Medical University, Nanjing
The Affiliated Hospital of Jiangsu University, Zhenjiang
Changzhou No.2 People's Hospital, Changzhou
The First People's Hospital of Changzhou, Changzhou
Suzhou Municipal Hospital-Endocrinology, Suzhou
The First Affiliated Hospital of Soochow University-Endocrinology, Suzhou
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Jinan Central Hospital, Ji'nan
Jinan Central Hospital, Jin'an
General Hospital of Tianjin Medical University-Endocrinology, Tianjin
General Hospital of Tianjin Medical University, Tianjin
The Second Hospital of Tianjin Medical University, Tianjin
Fujian Medical University Union Hospital-Endocrinology, Fuzhou
Chongqing University Three Gorges Hospital, Chongqing
The First People's Hospital of Changde City-Endocrinology, Changde
The Second Affiliated Hospital of Zhengzhou University-Endocrinology, Zhengzhou
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou
The First Affiliated Hospital of Henan University of Science and Technology-Endocrinology, Luoyang
The First Affiliated Hospital of Henan university of Science, Luoyang
Huaihe Hospital of Henan University-Endocrinology, Kaifeng
Huaihe Hospital of Henan University, Kaifeng
Huizhou Central People's Hospital-Endocrinology, Huizhou
Harrison International Peace Hospital-Endocrinology, Hengshui
The Second Hospital of Hebei Medical University-Endocrinology, Shijiazhuang
The Second Hospital of Hebei Medical University, Shijiazhuang
Lead Sponsor
Novo Nordisk A/S
INDUSTRY